Combining iPSC derived effector cell types for immunotherapy use
US12275955B2 · kind B2 · utility
0Cited by
13References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2021 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Jun 18, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2506/45
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors or additional cells in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.